Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation
Open Access
- 27 February 2009
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 84 (5) , 283-286
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapyLeukemia, 2007
- Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du MyélomeBlood, 2007
- Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosisLeukemia, 2006
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletionsBritish Journal of Haematology, 2004
- Genetics and Cytogenetics of Multiple MyelomaCancer Research, 2004
- Treatment of multiple myelomaBlood, 2004
- Clinical and biologic implications of recurrent genomic aberrations in myelomaBlood, 2003
- Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myelomaBone Marrow Transplantation, 1999
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996